-- 根據週四提交給澳洲證券交易所的文件顯示，Orthocell（ASX：OCC）已在加拿大完成其Remplir神經修復設備的首次商業銷售，這是其外周神經重建產品全球推廣進程中的一個里程碑。 該公司表示，Remplir目前已獲准在澳洲、紐西蘭、美國、新加坡、香港和加拿大銷售並產生收入，並計劃在2026年下半年獲得歐盟和英國市場的批准後，進一步拓展市場。 Orthocell補充道，截至3月31日，公司持有超過4,800萬澳元的現金，且無任何債務。
Related Articles
International
Saudi Arabia's Quarterly GDP Down 1.5% in Q1, Flash Data Shows
Saudi Arabia's seasonally adjusted real gross domestic product decreased 1.5% on a quarterly basis in the first quarter, compared with a 1.4% rise in the prior three-month period, flash data from the General Authority for Statistics showed Thursday.Annually, the Saudi Arabian economy grew 2.8% during the three-month period, after a 5% increase in the previous quarter.
$^TASI
Asia
Diagens Biotechnology's 2025 Loss Widens
Hangzhou Diagens Biotechnology (HKG:2526) booked 67.1 million yuan in attributable loss for 2025, widening from a loss of 43.4 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.The medical imaging products maker's shares gained nearly 3% in afternoon trade Thursday.Loss per share was 0.84 yuan, compared with 0.55 yuan in 2024.Revenue more than doubled year on year to 164.4 million yuan from 70.4 million yuan.
$HKG:2526
Asia
Daqin Railway Q1 Profit Down 7%; Shares Slip 3%
Daqin Railway Co (SHA:601006) posted first-quarter attributable net profit of 2.38 billion yuan, down 6.9% from 2.56 billion yuan the previous year.Earnings per share slid to 0.12 yuan from 0.13 yuan, according to a Thursday filing with the Shanghai bourse.Operating revenue climbed 4.3% year over year to 18.6 billion yuan from 17.8 billion yuan.Shares of the railway operator declined 3% in recent trade.
$SHA:601006